An Introduction to Haematological Malignancies
In recent years, advances in our understanding of the pathological mechanisms underlying haematological malignancies have led to improved outcomes. Several novel drug classes are now emerging, including chimeric antigen receptor (CAR) T-cell therapy, molecular targeted therapies, bispecific T-cell engaging antibodies, CD47 blockade therapy and antibody-drug conjugates. Many challenges remain, however, including how best to combine agents and determining where new therapies fit into the treatment paradigm.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.”
Our supporting partners do not constitute an endorsement of the content on this page.
Haematological Malignancies Content
Shaji Kumar, ASCO 2021: The EQUATE Trial, a Quadruplet Regimen for Multiple Myeloma
We were delighted to talk with Dr Shaji Kumar (Mayo Clinic, Rochester, MN, USA) about the EQUATE trial, developing a quadruplet regimen for newly-diagnosed multiple myeloma, including bortezomib, lenalidomide, dexamethasone and daratumumab. The abstract ‘ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended […]
Efstathios Kastritis, ASCO 2021: Results from the Phase 3 ANDROMEDA Study
touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at ASCO 2021 to discuss the updated results from the phase 3 ANDROMEDA study. The abstract ‘Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results […]
Modulation of Apoptosis Pathways in the Biology and Treatment of Multiple Myeloma
touchREVIEWS in Oncology & Haematology. 2021;17(1):48-54 DOI: https://doi.org/10.17925/OHR.2021.17.1.48
Multiple myeloma is a plasma cell malignancy that typically develops in individuals in their late 60s with an average survival time of ~8 years.1 Despite recent advances in treatment, multiple myeloma remains largely incurable due to development of drug resistance in tumour cells. Patients often relapse even after autologous stem cell transplant and multiple lines […]
The role of measurable residual disease in acute lymphoblastic leukaemia
Watch leading experts Aaron Logan, Joseph Khoury and Nicola Gökbuget discuss the importance of measurable residual disease reporting in acute lymphoblastic lymphoma, as well as best practice techniques, potential limitations, and future directions.
- Evaluate the evolving treatment landscape for acute lymphoblastic leukaemia
- Appraise the benefits and limitations of performing and reporting results for measurable residual disease
- Summarize how clinicians and pathologists can collaborate to use measurable residual disease testing to guide disease management
New Approaches to Allogeneic Haematopoietic Cell Transplantation
touchREVIEWS in Oncology & Haematology. 2021;17(1):28-35 DOI: https://doi.org/10.17925/OHR.2021.17.1.28
Allogeneic haematopoietic cell transplantation (allo-HCT) has a bi-faceted role in the treatment of haematopoietic malignancies. First, allo-HCT gives high-dose chemotherapy a chance to reduce the leukaemic burden; second, it allows graft-originated natural killer and T cells to initiate an adoptive immunotherapy effect against leukaemic cells via tumour-specific antigens, tumour-associated antigens and minor histocompatibility antigens.1–6 Allo-HCT plays […]
Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML
touchONCOLOGY meets with Prof. Andreas Hochhaus to discuss the clinical development of asciminib and its potential as a therapy for chronic myeloid leukaemia. The abstract ‘Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic […]
Othman Al-Sawaf, ASH 2020 – Venetoclax-obinutuzumab and the CLL14 Trial
Dr Othman Al-Sawaf joins touchONCOLOGY to discuss the CLL14 trial and the impact of venetoclax-obinutuzumab treatment on clonal growth and the potential of its use in chronic lymphocytic leukaemia. The abstract ‘Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial’ (Abstract number 127) was presented at the 62nd American Society […]
Shaji Kumar, ASH 2020 – Highlights from ASH 2020
It was a pleasure to speak with our Editor-in-Chief, Shaji Kumar (Mayo Clinic, Rochester, MN, USA) to discuss the use of MEDI2228 (Clinical Trial Identifier: NCT03489525) and anti-BCMA CAR-T cells (Clinical Trial Identifier: NCT03915184) in the treatment of patients with relapsed/refractory multiple myeloma and to find out his personal highlights from this year’s congress. The […]
Latest Developments in Cellular Therapy for Multiple Myeloma
Oncology & Hematology Review (US). 2020;16(2):111-8 DOI: https://doi.org/10.17925/OHR.2021.16.2.111
Multiple myeloma (MM) is a malignant clonal disorder of plasma cells in the bone marrow, and more than 32,000 new cases are expected in the USA each year.1 Many clinical advances, including novel drugs and continuous therapy with treatment sequencing, have improved survival statistics.2 Despite this, MM remains largely incurable and the relapsed/refractory population remains vulnerable […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!